---
title: "Weekly Recap | Abbvie -3.58%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297386660.md"
description: "AbbVie (ABBV) fell 3.58% this week to close at $255.48, while the S&P 500 gained 0.49%, leaving the stock down about 4.07 percentage points relative to the benchmark. The week opened on Monday (24 August) at $263.99, peaked at $266.91 intraday, then drifted lower across the following three sessions. Friday (28 August) saw the stock touch the week’s low of $255.08 before settling nearby. Weekly amplitude was 4.48%, with trading volume below its recent median level."
datetime: "2026-08-29T05:11:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297386660.md)
  - [en](https://longbridge.com/en/news/297386660.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297386660.md)
generator: "portal-rs"
---

# Weekly Recap | Abbvie -3.58%, most brokers rate it buy

## The Week

AbbVie (ABBV) fell 3.58% this week to close at $255.48, while the S&P 500 gained 0.49%, leaving the stock down about 4.07 percentage points relative to the benchmark. The week opened on Monday (24 August) at $263.99, peaked at $266.91 intraday, then drifted lower across the following three sessions. Friday (28 August) saw the stock touch the week’s low of $255.08 before settling nearby. Weekly amplitude was 4.48%, with trading volume below its recent median level.

## Key Events

This week’s company-specific news centred on the pipeline. Midweek, GUBRA disclosed that AbbVie started a Phase 2 trial of the obesity candidate ABBV-295, triggering a $50 million milestone payment. Around the same time, AbbVie presented lung cancer data ahead of WCLC 2026, drawing market attention. On Thursday (27 August), the company filed a regulatory submission with the EMA for SKYRIZI (risankizumab) subcutaneous induction in adults with moderately to severely active Crohn’s disease. Several institutional investors also disclosed modest increases in ABBV holdings during the week.

## Analyst Ratings

As of this week, 31 institutions cover AbbVie. Of these, 17 rate it buy, 8 overweight, 5 hold, and 1 underweight, with no sell ratings. The consensus rating is buy, and the consensus target is $276.59, about 8.26% above the current price. Target prices range from $200 to $328, reflecting a wide spread of views. Within the biotech sector, AbbVie ranks 3rd out of 505 companies for analyst ratings.

## The Week Ahead

Next week brings a run of US macro data: the Dallas Fed manufacturing index on Monday, and the S&P Global manufacturing PMI final and ISM manufacturing PMI on Tuesday (1 September). The ISM print has a prior reading of 55.6 and a forecast of 55.2. Wednesday (2 September) brings ADP private payrolls and factory orders. There are no scheduled AbbVie earnings, but the macro releases could shape overall risk appetite.

## In Short

Ratings lean constructive. Of 31 brokers, 25 rate it buy or overweight, the consensus target sits above spot, and the sector ranking is strong. Yet the share price declined this week, and the latest daily money-flow snapshot shows mixed direction across retail and mid-sized orders. The next leg will hinge on macro sentiment and further news on the ABBV-295 obesity programme.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Earnings Snapshot: AbbVie beats Q3 EPS and revenue views, raises full-year earnings guidance](https://longbridge.com/en/news/303746794.md)
- [AbbVie’s Qulipta outperforms topiramate in Phase 3 migraine prevention trial](https://longbridge.com/en/news/303539322.md)
- [AbbVie Raises 2026 Outlook, Boosts Dividend](https://longbridge.com/en/news/303791879.md)
- [AbbVie Seeks FDA Approval for Etentamig to Treat Multiple Myeloma](https://longbridge.com/en/news/303226486.md)
- [AbbVie submits etentamig BLA for multiple myeloma](https://longbridge.com/en/news/303259769.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**